Denosumab after total hip arthroplasty - Authors' reply
- PMID: 38287638
- DOI: 10.1016/S2665-9913(21)00142-9
Denosumab after total hip arthroplasty - Authors' reply
Conflict of interest statement
RE declares grants from Alexion, Amgen, Immunodiagnostic Systems, Roche, and Nittobo; and personal fees from Amgen, Immunodiagnostic Systems, Roche, GlaxoSmithKline Nutrition, Mereo, Sandoz, Nittobo, AbbVie, Samsung, Haoma Medica, Elsevier, CL Bio, Foundation for the National Institutes of Health, Viking, University of California San Francisco, Biocon, and Lyramid, outside the submitted work. All authors report a grant from Amgen, in relation to the work discussed here.
Publication types
LinkOut - more resources
Full Text Sources